Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Müller

Showing results (601-610 of 651) with videos related to

Pageof 66
Sort By:
British Journal of Haematology|February 2, 2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative StudySabine Kayser, Robert K Hills, Ralitsa Langova, et al.
Molecular Therapy. Oncology|February 20, 2026
A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based constructAlexandros Kourtesakis, Hiu Nam Hannah Chow, Eileen Bailey, et al.
British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Blood|July 20, 2022
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1Maike Janssen, Christina Schmidt, Peter-Martin Bruch, et al.
Journal of Hematology & Oncology|July 22, 2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trialMaria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, et al.
Science Immunology|February 7, 2025
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myelomaRaphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, et al.
Cell Reports|April 25, 2025
Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging miceJung-Seok Kim, Sébastien Trzebanski, Sun-Hye Shin, et al.
Haematologica|February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemiaSabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Pageof 66

Showing results (601-610 of 651) with videos related to

Sort By:
Pageof 66
British Journal of Haematology|February 2, 2021
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative StudySabine Kayser, Robert K Hills, Ralitsa Langova, et al.
Molecular Therapy. Oncology|February 20, 2026
A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based constructAlexandros Kourtesakis, Hiu Nam Hannah Chow, Eileen Bailey, et al.
British Journal of Cancer|August 4, 2023
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C Enßle, Sebastian Wolf, Sebastian Scheich, et al.
Blood|July 20, 2022
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1Maike Janssen, Christina Schmidt, Peter-Martin Bruch, et al.
Journal of Hematology & Oncology|July 22, 2023
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trialMaria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, et al.
Science Immunology|February 7, 2025
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myelomaRaphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, et al.
Cell Reports|April 25, 2025
Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging miceJung-Seok Kim, Sébastien Trzebanski, Sun-Hye Shin, et al.
Haematologica|February 23, 2023
Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemiaSabine Kayser, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Trials|November 4, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLSonia Jaramillo, Johannes Krisam, Lucian Le Cornet, et al.
Pageof 66